MAIA Stock Overview
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
MAIA Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.68 |
| 52 Week High | US$3.07 |
| 52 Week Low | US$0.82 |
| Beta | 0 |
| 1 Month Change | 9.84% |
| 3 Month Change | 98.52% |
| 1 Year Change | 12.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAIA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 36.7% | 0.4% | 1.0% |
| 1Y | 12.1% | 0.9% | 21.9% |
Return vs Industry: MAIA exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: MAIA underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| MAIA volatility | |
|---|---|
| MAIA Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MAIA's share price has been volatile over the past 3 months.
Volatility Over Time: MAIA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 13 | Vlad Vitoc | www.MAIABiotech.com |
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company’s lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents.
MAIA Biotechnology, Inc. Fundamentals Summary
| MAIA fundamental statistics | |
|---|---|
| Market cap | US$55.16m |
| Earnings (TTM) | -US$19.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs MAIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAIA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.77m |
| Earnings | -US$19.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MAIA perform over the long term?
See historical performance and comparison